Unmet Challenges in COVID-19 Prevention for Immunocompromised Individuals: A Consensus Analysis from Portugal
DOI:
https://doi.org/10.20344/amp.9949Keywords:
COVID-19/prevention and control, Delphi Technique, Immunocompromised Host, Portugal, SARS-CoV-2Abstract
Introduction: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), resulted in significant disease burden and mortality. Despite vaccination successes, new virus variants persist, affecting unvaccinated and immunocompromised individuals (ICI) severely. These high-risk groups face elevated mortality and hospitalization rates. Vigilance and targeted health measures remain crucial post-pandemic. The aim of this study was to develop consensus on the unmet needs in COVID-19 prevention among ICI.
Methods: We performed a Delphi study involving 45 experts, including physicians, health managers, policymakers, public health experts, members of medical societies and patient organizations. Consensus was achieved at 65% for each identified strategy using a scale ranging from “strongly agree” to “strongly disagree.” Three Delphi rounds were conducted to address four key questions: identifying unmet needs in COVID-19 prevention for ICI; identifying the characteristics that distinguish ICI as a susceptible group; determining the main outcomes of COVID-19 in ICI; and indicating action plans for protecting ICI. The first round involved voting on pre-identified indicators. The second and third rounds involved analyzing the gathered information and voting on each indicator to achieve consensus.
Results: A retention rate of 80% was achieved. Out of 89 valid indicators analyzed, 23 achieved consensus. These included: eight indicators highlighting the importance of raising awareness about COVID-19 and vaccination outcomes, ensuring safety and understanding, and developing targeted immunization strategies for ICI; five indicators identifying susceptible groups within ICI, such as individuals undergoing chemotherapy or radiotherapy, those with primary immunodeficiencies, solid organ transplant recipients, patients with chronic kidney disease, and bone marrow transplant recipients; two indicators showing improvements in clinical outcomes and reduced hospitalizations; and eight indicators recommending the development of effective therapies, more immunogenic vaccines, and treatments for viral infections in ICI.
Conclusion: The study emphasized the importance of targeted immunization strategies, monitoring, and tailored education to address diverse needs of ICI. These findings provide a foundation for future policies to effectively manage and protect ICI during and beyond the COVID-19 pandemic.
Downloads
References
World Health Organization. COVID-19 cases. WHO COVID-19 dashboard. [cited 2024 Jul 24]. Available from: https://data.who.int/dashboards/covid19/cases?n=c.
Mekkawi R, Elkattan BA, Shablak A, Bakr M, Yassin MA, Omar NE. COVID-19 vaccination in cancer patients: a review article. Cancer Control. 2022;29:107327482211062. DOI: https://doi.org/10.1177/10732748221106266
Tan TT, Ng HJ, Young B, Khan BA, Shetty V, Azmi N, et al. Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews. Expert Rev Vaccines. 2023;22:341-65. DOI: https://doi.org/10.1080/14760584.2023.2191716
Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021;76:428-55. DOI: https://doi.org/10.1111/all.14657
Kant S, Kronbichler A, Salas A, Bruchfeld A, Geetha D. Timing of COVID-19 vaccine in the setting of anti-cd20 therapy: a primer for nephrologists. Kidney Int Rep. 2021;6:1197-9. DOI: https://doi.org/10.1016/j.ekir.2021.03.876
Gentile I, Schiano Moriello N. COVID-19 prophylaxis in immunosuppressed patients: beyond vaccination. PLoS Med. 2022;19:e1003917. DOI: https://doi.org/10.1371/journal.pmed.1003917
Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised patients with protracted COVID-19: a review of “long persisters”. Curr Transplant Rep. 2022;9:209-18. DOI: https://doi.org/10.1007/s40472-022-00385-y
Jena A, James D, Singh AK, Dutta U, Sebastian S, Sharma V. Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:1456-79.e18. DOI: https://doi.org/10.1016/j.cgh.2022.02.030
Singson JR, Kirley PD, Pham H, Rothrock G, Arminstead I, Meek J, et al. Factors associated with severe outcomes among immunocompromised adults hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:878-84. DOI: https://doi.org/10.15585/mmwr.mm7127a3
Portugal. Directorate-General of Health. Number of new cases and deaths per day, last updated on July 24. [cited 2024 Jul 24]. Available from: https://covid19.min-saude.pt/numero-de-novos-casos-e-obitos-por-dia/.
Wise J. Covid-19: WHO declares end of global health emergency. BMJ. 2023;381:1041. DOI: https://doi.org/10.1136/bmj.p1041
Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. 2024. [cited 2024 May 03]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html.
Rzymski P, Camargo CA, Fal A, Flisiak R, Gwenzi W, Kelishadi R, et al. COVID-19 vaccine boosters: the good, the bad, and the ugly. Vaccines. 2021;9:1299. DOI: https://doi.org/10.3390/vaccines9111299
Mohamed K, Rzymski P, Islam MS, Makuku R, Mushtaq A, Khan A, et al. COVID-19 vaccinations: the unknowns, challenges, and hopes. J Med Virol. 2022;94:1336-49. DOI: https://doi.org/10.1002/jmv.27487
Sun J, Zheng Q, Madhira V, Olex AL, Anzalone AJ, Vinson A, et al. Association between immune dysfunction and COVID-19 breakthrough infection after SARS-CoV-2 vaccination in the US. JAMA Intern Med. 2022;182:153-62. DOI: https://doi.org/10.1001/jamainternmed.2021.7024
Primorac D, Vrdoljak K, Brlek P, Pavelic E, Molnar V, Matišić V, et al. Adaptive immune responses and immunity to SARS-CoV-2. Front Immunol. 2022;13:848582. DOI: https://doi.org/10.3389/fimmu.2022.848582
Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol. 2021;11:116-29. DOI: https://doi.org/10.5662/wjm.v11.i4.116
McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38:655-62. DOI: https://doi.org/10.1007/s11096-016-0257-x
Delbecq A, Van de Ven A, Gustafson D. Group techniques for program planning: a guide to nominal group and Delphi processes. Group Organ Stud. 1976;1.
Barrett D, Heale R. What are Delphi studies? Evid Based Nurs. 2020;23:68-9. DOI: https://doi.org/10.1136/ebnurs-2020-103303
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77-101. DOI: https://doi.org/10.1191/1478088706qp063oa
Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. J Adv Nurs. 2000;32:1008-15. DOI: https://doi.org/10.1046/j.1365-2648.2000.t01-1-01567.x
Shoham S, Batista C, Ben Amor Y, Ergonul O, Hassanain M, Hotez P, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine. 2023;59:101965. DOI: https://doi.org/10.1016/j.eclinm.2023.101965
Razonable RR. Protecting the vulnerable: addressing the COVID-19 care needs of people with compromised immunity. Front Immunol. 2024;15:1397040. DOI: https://doi.org/10.3389/fimmu.2024.1397040
Antinori A, Bausch-Jurken M. The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future. J Infect Dis. 2023;228:S4-12. DOI: https://doi.org/10.1093/infdis/jiad181
Bonanni P, Ceddia F, Dawson R. A call to action: current challenges and considerations for COVID-19 vaccination in immunocompromised populations. J Infect Dis. 2023;228:S70-6. DOI: https://doi.org/10.1093/infdis/jiad150
Negahdaripour M, Shafiekhani M, Moezzi SM, Amiri S, Rasekh S, Bagheri A, et al. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol. 2021;99:108021. DOI: https://doi.org/10.1016/j.intimp.2021.108021
Mikulska M, Sepulcri C, Dentone C, Magne F, Balletto E, Baldi F, et al. Triple combination therapy with 2 antivirals and monoclonal antibodies for persistent or relapsed severe acute respiratory syndrome coronavirus 2 infection in immunocompromised patients. Clin Infect Dis. 2023;77:280-6. DOI: https://doi.org/10.1093/cid/ciad181
Morawska M. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. Eur J Haematol. 2022;108:91-8. DOI: https://doi.org/10.1111/ejh.13722
Galmiche S, Luong Nguyen LB, Tartour E, de Lamballerie X, Wittkop L, Loubet P, et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect. 2022;28:163-77. DOI: https://doi.org/10.1016/j.cmi.2021.09.036
Lee AR, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376:e068632. DOI: https://doi.org/10.1136/bmj-2021-068632
Agrati C, Bartolini B, Bordoni V, Locatelli F, Capobianchi MR, Di Caro A, et al. Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response. Front Immunol. 2023;14:1147871. DOI: https://doi.org/10.3389/fimmu.2023.1147871
Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;72:340-50. DOI: https://doi.org/10.1093/cid/ciaa863
Bytyci J, Ying Y, Lee LYW. Immunocompromised individuals are at increased risk of COVID-19 breakthrough infection, hospitalization, and death in the post-vaccination era: a systematic review. Immun Inflamm Dis. 2024;12:e1259. DOI: https://doi.org/10.1002/iid3.1259
National Institutes of Health. Immunocompromised. COVID-19 treatment guidelines. 2024. [cited 2024 Jul 03]. Available from: https://www.covid19treatmentguidelines.nih.gov/special-populations/immunocompromised/.
Evans RA, Dube S, Lu Y, Yates M, Arnetorp S, Barnes E, et al. Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study. Lancet Reg Health Eur. 2023;35:100747. DOI: https://doi.org/10.1016/j.lanepe.2023.100747
Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183:996-1012.e19. DOI: https://doi.org/10.1016/j.cell.2020.09.038
Grifoni A, Alonzi T, Alter G, Noonan DM, Landay AL, Albini A, et al. Impact of aging on immunity in the context of COVID-19, HIV, and tuberculosis. Front Immunol. 2023;14:1146704. DOI: https://doi.org/10.3389/fimmu.2023.1146704
Jakharia N, Subramanian AK, Shapiro AE. COVID-19 in the immunocompromised host, including people with human immunodeficiency virus. Infect Dis Clin North Am. 2022;36:397-421. DOI: https://doi.org/10.1016/j.idc.2022.01.006
Danwang C, Noubiap JJ, Robert A, Yombi JC. Outcomes of patients with HIV and COVID-19 co-infection: a systematic review and meta-analysis. AIDS Res Ther. 2022;19:3. DOI: https://doi.org/10.1186/s12981-021-00427-y
Gorst SL, Seylanova N, Dodd SR, Harman NL, O’Hara M, Terwee CB, et al. Core outcome measurement instruments for use in clinical and research settings for adults with post-COVID-19 condition: an international Delphi consensus study. Lancet Respir Med. 2023;11:1101-14. DOI: https://doi.org/10.2139/ssrn.4317875
Rowe G, Wright G, McColl A. Judgment change during Delphi-like procedures: the role of majority influence, expertise, and confidence. Technol Forecast Soc Change. 2005;72:377-99. DOI: https://doi.org/10.1016/j.techfore.2004.03.004
Turtle L, Thorpe M, Drake TM, Knight SR, Harrison EM, Docherty AB, et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. PLoS Med. 2023;20:e1004086. DOI: https://doi.org/10.1371/journal.pmed.1004086
Saleem SM, Jan SS. Navigating the infodemic: strategies and policies for promoting health literacy and effective communication. Front Public Health. 2024;11:1324330. DOI: https://doi.org/10.3389/fpubh.2023.1324330
Whitaker JA. Immunization strategies to span the spectrum of immunocompromised adults. Mayo Clin Proc. 2020;95:1530-48. DOI: https://doi.org/10.1016/j.mayocp.2019.09.002
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
